Sixteen patients with advanced melanoma received IFN-α2A, 36 x 106 U/m2 i.m., on days 3-7 with 2.25 g/m2 DFMO p.o. on days 1-7. We observed no objective regressions. Median time to progression was 1.2 months with a median survival of 5.2 months. A flu-type syndrome was the predominant sequela. From the dose and schedule that we utilized, this regimen holds little promise against disseminated malignant melanoma.
|Original language||English (US)|
|Number of pages||3|
|Journal||American Journal of Clinical Oncology: Cancer Clinical Trials|
|State||Published - Jan 1 1990|
ASJC Scopus subject areas
- Cancer Research